Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor
10 mai 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs
05 mai 2021 07h30 HE
|
Heat Biologics
DURHAM, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the...
Heat Biologics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
26 avr. 2017 07h00 HE
|
Heat Biologics
DURHAM, N.C., April 26, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Presents New Preclinical Data from OncoSec Collaboration at the American Association for Cancer Research (AACR) Annual Meeting
05 avr. 2017 08h00 HE
|
Heat Biologics
Combining ComPACT DNA electroporation and cellular vaccination led to increased tumor antigen-specific CD8+ T cells, delayed tumor progression and improved overall survival in preclinical models ...
Heat Biologics Reports Fiscal Year 2016 Financial Results
31 mars 2017 07h00 HE
|
Heat Biologics
DURHAM, N.C., March 31, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Closes Public Offering of 5,000,000 Shares of Common Stock
28 mars 2017 16h01 HE
|
Heat Biologics
DURHAM, N.C., March 28, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Prices Offering of 5,000,000 Shares of Common Stock
23 mars 2017 08h00 HE
|
Heat Biologics
DURHAM, N.C., March 23, 2017 (GLOBE NEWSWIRE) -- HEAT BIOLOGICS, INC. (“HEAT”) (NASDAQ:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Announces Proposed Public Offering of Common Stock
22 mars 2017 16h03 HE
|
Heat Biologics
DURHAM, N.C., March 22, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against...
Heat Biologics Reports Positive Interim Phase 2 Lung Cancer Results in Patients Treated with HS-110 in Combination with a Checkpoint Inhibitor
21 mars 2017 07h00 HE
|
Heat Biologics
ELISPOT results suggest that HS-110 plays an integral role in tumor reduction and may enhance efficacy of checkpoint inhibitors in lung cancer patients Tumor reduction corresponds to enhanced immune...
Florida Department of Health Awards Three-Year Grant to Develop gp96-based Zika Vaccine
16 mars 2017 07h02 HE
|
Heat Biologics
Grant to fund Dr. Natasa Strbo’s Zika preclinical research at the University of Miami DURHAM, N.C., March 16, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the...